249 results on '"Marando, A."'
Search Results
2. Pneumothorax as first evidence of unknown lymphangioleiomyomatosis
3. Biosynthetic incorporation for visualizing bacterial glycans
4. Biphenotypic lung carcinoma with coexpression of TTF-1 and ΔNP63/P40 within most of the same individual cells: a further case confirming poor prognosis and a review of literature
5. Glaucoma
6. Contemporary adequacy of thromboprophylaxis in acutely ill medical patients in Switzerland: a bi-centric prospective cohort
7. What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review
8. P076 Comparing Four Different Simulated Shiftwork Schedules on Higher order Cognitive Function
9. O067 Comparison of Sleep Quantity and Quality during Watchkeeping Schedules
10. Preleukemic single-cell landscapes reveal mutation-specific mechanisms and gene programs predictive of AML patient outcomes
11. Author Correction: Multiparameter prediction of myeloid neoplasia risk
12. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies
13. The sleep, circadian, and cognitive performance consequences of watchkeeping schedules in submariners: A scoping review
14. Supplemental Figure from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
15. Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
16. Data from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
17. Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
18. Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
19. Data from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
20. Supplemental Figure from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
21. Multiparameter prediction of myeloid neoplasia risk
22. P442: DDX41 GERMLINE VARIANTS: POPULATION PREVALENCE, SIGNIFICANCE AND LEUKEMIC EVOLUTION
23. S121: MULTIPARAMETER PREDICTION OF MYELOID NEOPLASIA RISK
24. Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host–microbe interactions with oral commensals
25. Identification of d-arabinan-degrading enzymes in mycobacteria
26. Data from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
27. Supplementary Table from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
28. Data from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
29. Supplementary Data from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
30. Supplementary Table from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
31. Supplementary Table from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
32. Supplementary Table from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
33. Supplementary Data from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
34. Supplementary Figure from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
35. Supplementary Figure from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
36. Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
37. Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
38. Supplementary Table 1 from A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
39. Supplementary Figures 1-3 from A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
40. Supplementary Table 1 from A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
41. Supplementary Figures 1-3 from A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
42. Supplementary Figures Legends 1-3, Table Legend from A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
43. Supplementary Figures Legends 1-3, Table Legend from A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
44. Unaccompanied foreign minors and mental health: Implementation and evaluation of the RHS-15 screening procedure for unaccompanied foreign minors
45. Rapid Single-Shot Synthesis of the 214 Amino Acid-Long N-Terminal Domain of Pyocin S2
46. Dog1 Expression in Neuroendocrine Neoplasms: Potential Applications and Diagnostic Pitfalls
47. Cooling cities through urban green infrastructure: a health impact assessment of European cities
48. Abstract 1535: Application of human oral lectin ZG16B as a microbial glycan analysis probe (mGAP) to decode host-microbe interactions
49. Video-based surgical curriculum for open-globe injury repair, III: surgical repair
50. Evidence for Complementary and Alternative Therapies to Treat Glaucoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.